While modern TMT yields 5-year overall survival rates comparable to cystectomy in propensity-matched analyses, local recurrence or incomplete response still affects a substantial proportion of patients, highlighting the need for more effective regimens without compromising tolerability or quality of life. In this multicenter phase 2 trial, we integrated the PD-1 inhibitor pembrolizumab into a gemcitabine-based chemoradiation backbone. Patients received a single priming dose of pembrolizumab (200 mg), followed by maximal TURBT, and then hypofractionated external beam radiation therapy (52 Gy in 20 fractions) delivered with concurrent low-dose gemcitabine (27 mg/m² twice weekly) and additional pembrolizumab (every 3 weeks for three doses). This design leveraged both the radiosensitizing and immunomodulatory properties of low-dose gemcitabine, along with the potential for enhanced antigen presentation when checkpoint inhibition is introduced in the presence of intact tumor burden.
Methodology Highlights and Strengths:
The trial employed a pragmatic, multicenter design across five U.S. academic centers with a phase 1 safety lead-in using a 3+3 design, followed by an efficacy cohort of 48 patients (total enrollment 54). Eligibility focused on clinically localized T2–T4aN0M0 urothelial carcinoma in patients with good performance status and no prior PD-1/PD-L1 exposure — a population representative of those considered for bladder preservation in real-world practice. Notable design elements include:
- Uniform use of hypofractionated radiation (preferred intensity-modulated technique) and a consistent low-dose gemcitabine schedule.
- Mandatory response assessment at 12 weeks with cystoscopy, TURBT/biopsy, cytology, and cross-sectional imaging.
- A clinically relevant primary endpoint: 2-year bladder-intact disease-free survival (BIDFS), which captures not only oncologic events (muscle-invasive recurrence or metastasis) but also the need for salvage cystectomy — a critical patient-centered outcome.
Key Findings:
In the efficacy cohort, the 2-year BIDFS was 60% (95% CI 45–73%), which did not meet the ambitious statistical threshold of 80% (designed to detect a 20% absolute improvement over historical controls). However, other outcomes were encouraging: 2-year metastasis-free survival reached 81% (95% CI 66–92%) and overall survival 83% (95% CI 69–91%). The 12-week complete response rate was 56% per-protocol (rising to 77% in intention-to-treat analyses, accounting for clinically disease-free patients with incomplete evaluations). Safety was generally manageable and consistent with prior chemoradiation experiences, with grade ≥3 treatment-related adverse events in 25% of patients.
Common toxicities included diarrhea, cytopenias, and cystitis. Immune-related grade ≥3 events occurred in 10%, including colitis and one treatment-related death from colonic perforation. Notably, six patients ultimately underwent cystectomy — only one for recurrence and five for persistent treatment-related toxicity (these 5 patients had pathologic complete response at the time of surgery). This observation underscores a key tension: excellent local tumor control in some patients, yet augmented local inflammation potentially leading to functional bladder compromise. Exploratory analyses showed numerically similar outcomes in PD-L1–positive patients (modified proportion score ≥10), though incomplete biomarker data limits firm conclusions.
Limitations and Critical Considerations:
As a single-arm phase 2 study with a modest sample size, this trial cannot definitively establish superiority over standard TMT. The BIDFS endpoint, while patient-relevant, is composite and can be influenced by non-oncologic events such as toxicity-driven cystectomy. The higher-than-expected rate of late salvage cystectomy for toxicity (despite pathologic CR) raises important questions about whether the addition of pembrolizumab may exacerbate radiation-induced bladder or bowel inflammation in a subset of patients. Prior studies combining immunotherapy with chemoradiation have shown variable toxicity profiles, likely related to differences in radiation dosing, fractionation, and sequencing. Additional limitations include potential selection bias inherent to bladder-preservation trials, limited long-term functional bladder outcomes data, and the possibility of under-detection of distant events due to imaging schedules.
Clinical Implications and Future Directions:
This study provides important proof-of-concept that integrating PD-1 blockade into gemcitabine-based TMT is feasible and produces signals of meaningful antitumor activity, particularly with respect to systemic control (high MFS and OS). The results reinforce the biologic rationale for combining immunomodulatory chemotherapy, radiation, and checkpoint inhibition — a strategy that may enhance both local and distant disease control. However, the failure to meet the primary BIDFS threshold, combined with the toxicity-driven cystectomies, tempers enthusiasm for immediate routine adoption.
These findings appropriately caution against off-protocol incorporation of pembrolizumab into definitive chemoradiation outside of clinical trials. Fortunately, definitive answers are on the horizon. Ongoing randomized phase 3 trials — including KEYNOTE-992 (NCT04241185, pembrolizumab + chemoradiation) and S1806 (NCT03775265, atezolizumab + chemoradiation) — will clarify whether immunotherapy meaningfully improves outcomes in the bladder-preservation setting and better characterize the risk-benefit profile. In the broader context of MIBC management, this trial arrives at an exciting time. Perioperative enfortumab vedotin plus pembrolizumab has raised the bar for systemic therapy, and bladder-preservation strategies must now compete not only with cystectomy but with increasingly effective multimodal systemic approaches.
Future studies may explore optimized sequencing (e.g., more extended immunotherapy, biomarker-driven selection, or integration with antibody-drug conjugates), advanced radiation techniques, and rigorous patient-reported functional outcomes.
Conclusion:
We have delivered a well-conducted phase 2 trial that advances our understanding of immuno-chemoradiation for bladder preservation. While the regimen did not surpass the prespecified efficacy threshold for BIDFS, the observed metastasis-free and overall survival rates, coupled with manageable (though not negligible) toxicity, provide a strong rationale for continued investigation. As we await phase 3 data, this work reminds us that improving bladder preservation requires balancing oncologic efficacy, toxicity, and quality of life — goals that remain central to caring for patients with MIBC who prioritize organ retention.
Written by: Minas Economides, MD, Assistant Professor of Medicine, Laura and Isaac Perlmutter Cancer Center at NYU Langone Health and the NYU Grossman School of Medicine, New York, NY (on behalf of the study investigators)
Read the Abstract